3-methylfuro[2,3-d]pyrimidin-2(3H)-one | 876276-11-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃[2,3-d]嘧啶
• 英文名称: 3-methylfuro[2,3-d]pyrimidin-2(3H)-one
• 英文别名: 3-Methyl-3H-furo[2,3-d]pyrimidin-2-；3-methylfuro[2,3-d]pyrimidin-2-one
• CAS: 876276-11-8
• 化学式: C₇H₆N₂O₂
• mdl: MFCD09031501
• 分子量: 150.137
• InChiKey: UYQAJABEAGMWFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  41.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methylfuro[2,3-d]pyrimidin-2(3H)-one 在 溴 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以60%的产率得到6-bromo-3-methylfuro[2,3-d]pyrimidin-2(3H)-one
  参考文献：
  名称：

  6-（炔-1-基）呋喃并[2,3-d]嘧啶-2（3H）-一碱基和核苷衍生物的合成及生物学评价。

  摘要：

  在C6处带有长链烷基（或4-烷基苯基）取代基的呋喃[2,3-d]嘧啶-2（3H）-one的2'-脱氧核苷衍生物显示出显着的抗VZV（水痘带状疱疹病毒）效力和选择性，以及类似的2'，3'-二脱氧核苷衍生物显示出抗HCMV（人类巨细胞病毒）活性。我们现在报告一种合成方法，该方法能够制备长链6-（炔基-1-基）呋喃并[2,3-d]嘧啶-2（3H）-，其中棒状乙炔间隔基取代了4-取代基-在C6的苯环。已经制备了在N 3处具有甲基，β-d-呋喃呋喃糖基，β-d-阿拉伯呋喃糖基和2-脱氧β-d-赤-戊呋喃糖基取代基的类似物。2'-脱氧核苷系列中C6处的长链衍生物显示病毒编码的核苷激酶敏感的抗VZV活性。令人惊讶的是，3-甲基-6-（辛基-1-基）呋喃[2，

  DOI：

  10.1021/jm050867d
• 作为产物：
  描述：

  1-methyl-5-(trimethylsilylethynyl)uracil 在 氟化铵 、 copper(l) iodide 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 3-methylfuro[2,3-d]pyrimidin-2(3H)-one
  参考文献：
  名称：

  6-（炔-1-基）呋喃并[2,3-d]嘧啶-2（3H）-一碱基和核苷衍生物的合成及生物学评价。

  摘要：

  在C6处带有长链烷基（或4-烷基苯基）取代基的呋喃[2,3-d]嘧啶-2（3H）-one的2'-脱氧核苷衍生物显示出显着的抗VZV（水痘带状疱疹病毒）效力和选择性，以及类似的2'，3'-二脱氧核苷衍生物显示出抗HCMV（人类巨细胞病毒）活性。我们现在报告一种合成方法，该方法能够制备长链6-（炔基-1-基）呋喃并[2,3-d]嘧啶-2（3H）-，其中棒状乙炔间隔基取代了4-取代基-在C6的苯环。已经制备了在N 3处具有甲基，β-d-呋喃呋喃糖基，β-d-阿拉伯呋喃糖基和2-脱氧β-d-赤-戊呋喃糖基取代基的类似物。2'-脱氧核苷系列中C6处的长链衍生物显示病毒编码的核苷激酶敏感的抗VZV活性。令人惊讶的是，3-甲基-6-（辛基-1-基）呋喃[2，

  DOI：

  10.1021/jm050867d

文献信息

• 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20100074889A1

  公开（公告）日：2010-03-25

  The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
• NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20160058783A1

  公开（公告）日：2016-03-03

  The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.
• US8163707B2
  申请人：——

  公开号：US8163707B2

  公开（公告）日：2012-04-24
• US9085599B2
  申请人：——

  公开号：US9085599B2

  公开（公告）日：2015-07-21
• US9675632B2
  申请人：——

  公开号：US9675632B2

  公开（公告）日：2017-06-13